H-RIAWARTEL-OH

Ref. 3D-PP44446

Produktinformation

• Name: H-RIAWARTEL-OH
• Synonyme: NH2-Arg-Ile-Ala-Trp-Ala-Arg-Thr-Glu-Leu-OH

Beschreibung

Peptide H-RIAWARTEL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-RIAWARTEL-OH include the following: Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients MT Hueman , ZA Dehqanzada, TE Novak - Clinical cancer , 2005 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/11/20/7470/188544 Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients United States Military Cancer Institute Clinical MG Carmichael, LC Benavides - Journal of the , 2010 - Wiley Online Libraryhttps://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.24756 The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 LC Benavides, JD Gates, MG Carmichael, R Patel - Clinical Cancer , 2009 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/15/8/2895/74744 Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence From US Military Cancer Institute Clinical Trials Group Study JP Holmes, JD Gates, LC Benavides - Journal of the , 2008 - Wiley Online Libraryhttps://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.23772 Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I JP Holmes, GT Clifton, R Patil, LC Benavides - Cancer, 2011 - Wiley Online Libraryhttps://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25586 Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: US Military Cancer Institute GE Peoples, JP Holmes, MT Hueman - Clinical Cancer , 2008 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/14/3/797/179701 Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers GE Peoples, BW Anderson, TV Lee , JL Murray - Clinical cancer , 1999 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/5/12/4214/287769 of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US A Amin, LC Benavides, JP Holmes, JD Gates - Cancer Immunology , 2008 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0509-2

• Marke: Biosynth